L
Lynne V. Abruzzo
Researcher at Ohio State University
Publications - 175
Citations - 9491
Lynne V. Abruzzo is an academic researcher from Ohio State University. The author has contributed to research in topics: Chronic lymphocytic leukemia & Leukemia. The author has an hindex of 44, co-authored 173 publications receiving 8744 citations. Previous affiliations of Lynne V. Abruzzo include The Ohio State University Wexner Medical Center & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
A multidrug resistance transporter from human MCF-7 breast cancer cells
L. Austin Doyle,Weidong Yang,Lynne V. Abruzzo,Tammy Krogmann,Y. Gao,Arun K. Rishi,Douglas D. Ross,Douglas D. Ross +7 more
TL;DR: In this article, the authors identify a 2.4-kb mRNA that encodes a 663-aa member of the ATP-binding cassette superfamily of transporters that they termed breast cancer resistance protein (BCRP).
Journal ArticleDOI
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
Kami J. Maddocks,Amy S. Ruppert,Gerard Lozanski,Nyla A. Heerema,Weiqiang Zhao,Lynne V. Abruzzo,Arletta Lozanski,Melanie E. Davis,Amber Gordon,Lisa L. Smith,Rose Mantel,Jeffrey A. Jones,Joseph M. Flynn,Samantha Jaglowski,Leslie A. Andritsos,Farrukh T. Awan,Kristie A. Blum,Michael R. Grever,Amy J. Johnson,John C. Byrd,Jennifer A. Woyach +20 more
TL;DR: Sequencing data confirm initial reports associating mutations in BTK and PLCG2 with progression and clearly show that CLL progressions are associated with these mutations, while RT is likely not, and shows poor prognosis after discontinuation.
Journal ArticleDOI
FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome.
Sheng Xiao,Srinivasa R. Nalabolu,Jon C. Aster,Junli Ma,Lynne V. Abruzzo,Elaine S. Jaffe,Richard Stone,Sherman M. Weissman,Thomas J. Hudson,Jonathan A. Fletcher +9 more
TL;DR: The cloning of a novel fusion oncogene associated with a unique leukaemia/lymphoma syndrome is reported, demonstrating an FGFR1 oncogenic role and suggesting a tumorigenic mechanism in which ZNF198–FGFR1 activation results from ZNF 198 zinc-finger-mediated homodimerization.
Journal ArticleDOI
BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.
Jennifer A. Woyach,Amy S. Ruppert,Daphne Guinn,Amy Lehman,James S. Blachly,Arletta Lozanski,Nyla A. Heerema,Weiqiang Zhao,Joshua F. Coleman,Dan Jones,Lynne V. Abruzzo,Amber Gordon,Rose Mantel,Lisa L. Smith,Samantha McWhorter,Melanie E. Davis,Tzyy Jye Doong,Fan Ny,Margaret S. Lucas,Weihong Chase,Jeffrey A. Jones,Joseph M. Flynn,Kami J. Maddocks,Kerry A. Rogers,Samantha Jaglowski,Leslie A. Andritsos,Farrukh T. Awan,Kristie A. Blum,Michael R. Grever,Gerard Lozanski,Amy J. Johnson,John C. Byrd +31 more
TL;DR: It is shown that mutations in BTK and PLCG2 appear early and have the potential to be used as a biomarker for future relapse, suggesting an opportunity for intervention.
Journal ArticleDOI
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
Zijun Y. Xu-Monette,Lin Wu,Carlo Visco,Yu Chuan Tai,Alexander Tzankov,Wei-Min Liu,Santiago Montes-Moreno,Karen Dybkær,April Chiu,Attilio Orazi,Youli Zu,Govind Bhagat,Kristy L. Richards,Eric D. Hsi,X. Frank Zhao,William W.L. Choi,Xiaoying Zhao,J. Han van Krieken,Qin Huang,Jooryung Huh,Weiyun Z. Ai,Maurilio Ponzoni,Andrés J.M. Ferreri,Fan Zhou,Brad S. Kahl,Jane N. Winter,Wei Xu,Jianyong Li,Ronald S. Go,Yong Li,Miguel A. Piris,Michael Boe Møller,Roberto N. Miranda,Lynne V. Abruzzo,L. Jeffrey Medeiros,Ken H. Young +35 more
TL;DR: Assessment of TP53 mutation status is important for stratifying R-CHOP-treated patients into distinct prognostic subsets and has significant value in the design of future therapeutic strategies.